Wealth Enhancement Advisory Services LLC Sells 1,200 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Wealth Enhancement Advisory Services LLC reduced its stake in Medpace Holdings, Inc. by 16.5%, selling 1,200 shares during the second quarter.
• Analysts have mixed opinions on Medpace, with two analysts rating it as Buy, twelve as Hold, and three as Sell, while the consensus price target is $422.27.
• Insider trading activity has seen significant sales, including CEO August J. Troendle selling 48,487 shares valued at over $21 million, reducing his ownership by 4.80%.

Wealth Enhancement Advisory Services LLC lessened its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 16.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,076 shares of the company's stock after selling 1,200 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Medpace were worth $1,953,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Geneos Wealth Management Inc. increased its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after purchasing an additional 37 shares during the period. Brooklyn Investment Group increased its holdings in Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after purchasing an additional 71 shares during the period. Whittier Trust Co. increased its holdings in Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after purchasing an additional 35 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Medpace during the 1st quarter valued at about $60,000. Finally, Assetmark Inc. increased its holdings in Medpace by 24.9% during the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after purchasing an additional 43 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

MEDP has been the topic of a number of research analyst reports. Jefferies Financial Group upped their target price on Medpace from $400.00 to $450.00 and gave the stock a "hold" rating in a report on Tuesday, September 9th. Rothschild & Co Redburn downgraded Medpace from a "buy" rating to a "neutral" rating and upped their target price for the stock from $342.00 to $474.00 in a report on Wednesday, September 3rd. Barclays upped their target price on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. Rothschild Redb downgraded Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, September 3rd. Finally, Zacks Research downgraded Medpace from a "strong-buy" rating to a "hold" rating in a report on Monday, September 22nd. Two research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Reduce" and a consensus price target of $422.27.

Medpace Stock Up 1.8%

Shares of MEDP opened at $496.79 on Monday. The stock has a market cap of $13.95 billion, a P/E ratio of 36.94, a P/E/G ratio of 3.13 and a beta of 1.44. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $506.55. The business's 50 day moving average price is $464.83 and its 200-day moving average price is $361.31.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.10. The business had revenue of $603.31 million for the quarter, compared to analysts' expectations of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm's quarterly revenue was up 14.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insiders Place Their Bets

In related news, CEO August J. Troendle sold 48,487 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $451.69, for a total value of $21,901,093.03. Following the transaction, the chief executive officer directly owned 962,615 shares of the company's stock, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, President Jesse J. Geiger sold 41,801 shares of the company's stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $453.11, for a total value of $18,940,451.11. Following the completion of the transaction, the president directly owned 36,503 shares in the company, valued at $16,539,874.33. This trade represents a 53.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 161,266 shares of company stock worth $74,111,427 in the last three months. Corporate insiders own 20.30% of the company's stock.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.